KMT2D‐mutant lymphoma cells become hyper‐responsive to CD40 agonists when treated with KDM5 inhibitors, yielding potent synergy and enhanced efficacy in vivo.111 As several CD40 agonists are also in clinical trials for DLBCL, this is an appealing rational therapy for KMT2D mutant FLs and DLBCLs. This evidence concerns the gene CD40 and diffuse large B-cell lymphoma.